As such, for substrates that are anti-apoptotic regulators, potential inhibition of cognate cathepsin proteases overexpressed during cancer development, can predictably have the effect of enhancing the levels of certain anti-apoptotic Bcl-2 sub-family members, and thus drive cancer progression. This evidence concerns the gene BCL2 and cancer.